SCHEMBL4528740

SCHEMBL4528740

CNc1nc(N)nc2cc(-c3ccccc3C#N)ccc12

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 7/20 0.57
CYP3A4 P08684 7/20 0.57
ALDH1A1 P00352 6/20 0.57
CLK4 Q9HAZ1 5/20 0.57
HSD17B10 Q99714 5/20 0.57
MAPK1 P28482 3/20 0.57
DHFR P00374 4/20 0.47
HPGD P15428 2/20 0.43
PTPN1 P18031 4/20 0.43
CYP2C19 P33261 4/20 0.42
USP2 O75604 2/20 0.42
CYP2D6 P10635 2/20 0.42
LMNA P02545 1/20 0.42
ALOX5AP P20292 1/20 0.42
FEN1 P39748 1/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
CYP2C9 P11712 2/20 0.42
TSHR P16473 2/20 0.42
BLM P54132 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4519688 0.83 DHFR (0.52) CYP1A2CYP3A4CLK4HSD17B10DHFR
SCHEMBL4536277 0.83 CHUK (0.46) CYP1A2CYP3A4ALDH1A1CLK4HSD17B10
SCHEMBL4515183 0.82 PTPN1 (0.59) CYP1A2CYP3A4CLK4HSD17B10DHFR
SCHEMBL4526439 0.81 DHFR (0.50) DHFRPTPN1ALOX5APFEN1NLRP3
SCHEMBL4524950 0.81 PTPN1 (0.60) CYP1A2CYP3A4HSD17B10MAPK1DHFR
SCHEMBL4529705 0.81 PTPN1 (0.60) DHFRPTPN1NLRP3
SCHEMBL4521232 0.79 DHFR (0.73) CYP1A2CYP3A4ALDH1A1CLK4HSD17B10
SCHEMBL13888549 0.79 PTPN1 (0.57) DHFRPTPN1NLRP3
SCHEMBL4521004 0.79 ALDH1A1 (0.59) CYP1A2CYP3A4ALDH1A1CLK4HSD17B10
SCHEMBL4354963 0.79 CYP1A2 (0.55) CYP1A2CYP3A4ALDH1A1CLK4HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090105477-A1 Quinazoline Protein Tyrosine Phosphatase Inhibitors BERTHEL STEVEN JOSEPH 2009-04-23 US claimed
CN-101056865-A Aminoquinazolines compounds HOFFMANN LA ROCHE (CH) 2007-10-17 CN claimed
EP-1812409-A1 AMINOQUINAZOLINES COMPOUNDS F. Hoffmann-Roche AG (CH) 2007-08-01 EP claimed
US-20060211715-A1 Quinazoline protein tyrosine phosphatase inhibitors BERTHEL STEVEN J 2006-09-21 US claimed
WO-2006050843-A1 AMINOQUINAZOLINES COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2006-05-18 WO claimed
US-20090105477-A1 Quinazoline Protein Tyrosine Phosphatase Inhibitors BERTHEL STEVEN JOSEPH 2009-04-23 US disclosed
US-20090105477-A1 Quinazoline Protein Tyrosine Phosphatase Inhibitors BERTHEL STEVEN JOSEPH 2009-04-23 US disclosed
US-20090105477-A1 Quinazoline Protein Tyrosine Phosphatase Inhibitors BERTHEL STEVEN JOSEPH 2009-04-23 US disclosed
CN-101056865-A Aminoquinazolines compounds HOFFMANN LA ROCHE (CH) 2007-10-17 CN disclosed
EP-1812409-A1 AMINOQUINAZOLINES COMPOUNDS F. Hoffmann-Roche AG (CH) 2007-08-01 EP disclosed
US-20060211715-A1 Quinazoline protein tyrosine phosphatase inhibitors BERTHEL STEVEN J 2006-09-21 US disclosed
WO-2006050843-A1 AMINOQUINAZOLINES COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2006-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105477-A1 Quinazoline Protein Tyrosine Phosphatase Inhibitors PTPN5, PTPN1, PTPN7 CYP1A2 671/4885CYP3A4 1394/4885ALDH1A1 1591/4885
US-20060211715-A1 Quinazoline protein tyrosine phosphatase inhibitors PTPN5, PTPN1, PTPN7 CYP1A2 671/4885CYP3A4 1394/4885ALDH1A1 1591/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.